Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$156.66-2.74%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · ALNY
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -39.9% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 27.4% |
Growth built into the price is above our model estimate.
The price assumes 67.3 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 116 industry peers · Company calendar date is not available
ALNY — officer change
Dated 2026-11-05
EVP, Chief Commercialization Officer — Tolga Tanguler: The filing announces the planned departure of a senior executive (EVP/CCO) in December 2026, which constitutes a genuine loss of a sitting officer but is not necessarily negative as it is a planned exit with a separation agreement.
Why it matters: A trial start would move the Huntington's disease drug beyond early testing. The company said the start depends on talks with regulators.
Supportive ifAfter talks with regulators, Alnylam starts the key brezosiran study in 2027. The study uses a placebo control.
Worry ifAlnylam delays the start beyond 2027 or reports a safety issue that blocks the study.
Why it matters: The Phase 2 study finished enrollment. Its results will test whether early drug activity supports further work in this disease.
Watch forAlnylam reports Phase 2 results. They show a clear benefit on the study's main measure. No new serious safety issues linked to the drug arise.
Also watch forThe study misses its main measure or reports a serious safety issue linked to the drug.
Why it matters: The AHA meeting runs November 6–9, 2026. The results will add longer-term data on vutrisiran for ATTR-CM.
Watch forThe AHA report shows benefits continue at two years. This covers death or repeat heart events versus the study control.
Also watch forThe AHA report shows no continued benefit at two years on death or repeat heart events.
Why it matters: Alnylam cut its 2026 TTR sales range in Q2, then reported 59% TTR growth in Q3. Q4 sales will show whether demand holds.
Watch forQ4 results put 2026 TTR net product revenue at or above $4.2 billion, the low end of the latest range.
Also watch forQ4 results put 2026 TTR net product revenue below $4.2 billion.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$171 on $10,000 · ±1.7% | How much price usually moves either way. |
| Bad day | $470 loss on $10,000 · 4.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,690 loss on $10,000 · 66.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Management kept its full-year non-GAAP R&D and SG&A range at $2.7B–$2.8B. Q4 results will show if spending stays in range.
Worry ifFull-year non-GAAP R&D and SG&A expenses exceed $2.8 billion.
Less concerning ifFull-year non-GAAP R&D and SG&A expenses total $2.7 billion to $2.8 billion.